title: A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
abstract: Follicular lymphoma (FL) cells express CD20 and are associated in most cases with the t(14;18) chromosomal translocation. A multicentre study was undertaken between January 1997 and January 1998 to assess the complete response rate (CR) and overall response rate (RR) to rituximab, a chimaeric anti-CD20 monoclonal antibody. Seventy patients with previously treated FL received rituximab (375 mg/m2/week x4, by intravenous infusion). Restaging studies were performed 1 and 2 months after therapy. Molecular monitoring for the presence of cells harbouring the Bcl-2/JH gene rearrangement in the peripheral blood (PB) and bone marrow (BM) was performed before and after treatment using a two-step semi-nested polymerase chain reaction (PCR) assay. The overall RR was 32/70 (46%), being highest in patients who had received only one previous treatment (12/15, 80%). However, only two patients achieved a CR. The median duration of response was 11 months. Thirteen of 21 evaluable 'PCR-positive' patients (62%) became 'PCR-negative' in PB and/or BM samples 1 month after rituximab, although this did not correlate with clinical response. Treatment was generally well tolerated, although one patient developed Stevens-Johnson syndrome. Rituximab was shown to be active in FL, and in some cases PB and/or BM became PCR negative. Studies in combination with cytotoxic chemotherapy to increase the CR rate are warranted.
authors.affiliation: Imperial Cancer Research Fund Medical Oncology Unit, St. Bartholomew's Hospital, London, UK.
authors.forename: J M
authors.initials: JM
authors.lastname: Foran
authors.forename: R K
authors.initials: RK
authors.lastname: Gupta
authors.forename: D
authors.initials: D
authors.lastname: Cunningham
authors.forename: R A
authors.initials: RA
authors.lastname: Popescu
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
authors.forename: J W
authors.initials: JW
authors.lastname: Sweetenham
authors.forename: R
authors.initials: R
authors.lastname: Pettengell
authors.forename: P W
authors.initials: PW
authors.lastname: Johnson
authors.forename: E
authors.initials: E
authors.lastname: Bessell
authors.forename: B
authors.initials: B
authors.lastname: Hancock
authors.forename: K
authors.initials: K
authors.lastname: Summers
authors.forename: J
authors.initials: J
authors.lastname: Hughes
authors.forename: A Z
authors.initials: AZ
authors.lastname: Rohatiner
authors.forename: T A
authors.initials: TA
authors.lastname: Lister
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D015321:Gene Rearrangement; D019254:Genes, bcl-2; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D051379:Mice; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D011993:Recombinant Fusion Proteins; D000069283:Rituximab